Form SC14D9C JUNIPER PHARMACEUTICALS Filed by: JUNIPER PHARMACEUTICALS INC
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(RULE 14d-101)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Juniper Pharmaceuticals, Inc.
(Name of Subject Company)
Juniper Pharmaceuticals, Inc.
(Name of Person(s) Filing Statement)
Common Stock, par value $0.01 per Share
(Title of Class of Securities)
48203L107
(CUSIP Number of Class of Securities)
Alicia Secor
President and Chief Executive Officer
33 Arch Street
Suite 3110
Boston, Massachusetts, 02110
(617) 639-1500
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person(s) Filing Statement)
With copies to:
Stuart M. Cable
Michael H. Bison
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000
☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 5.03, 8.01 and 9.01 of the Current Report on Form 8-K filed by Juniper Pharmaceuticals, Inc. on July 3, 2018 (including all exhibits attached thereto) is incorporated herein by reference.